CuchelMBruckertEGinsbergHN, et al.Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J2014; 35: 2146–2157.
2.
LelliNGarutiRGhiselliniM, et al.Occurrence of multiple aberrantly spliced mRNAs of the LDL-receptor gene upon a donor splice site mutation that causes familial hypercholesterolemia (FHBenevento). J Lipid Res1995; 36: 1315–1324.
3.
RaalFJHonarpourNBlomDJ, et al.TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet2015; 385: 341–350.
4.
PećinIHartgersMLHovinghGK, et al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
5.
SchwartzJWintersJLPadmanabhanA, et al.Guidelines on the use of therapeutic apheresis in clinical-practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue. J Clin Apher2013; 28: 145–284.
6.
RaalFJHovinghGKCatapanoAL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis2018; 277: 483–492.
7.
AjufoERaderDJ. New therapeutic approaches for familial hypercholesterolemia. Annu Rev Med2018; 69: 113–131.
8.
LeipoldRRaalFIshakJ, et al.The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol2017; 24: 1843–1850.
9.
ZentiMGAltomariALupoMG, et al.From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol2018; 25: 1843–1851.
10.
SbranaFDal PinoBBigazziF, et al.Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled. Eur J Prev Cardiol2019; 26: 782–782.
11.
RuscicaMFerriNMacchiC, et al.Lipid lowering drugs and inflammatory changes: An impact on cardiovascular outcomes?Ann Med2018; 50: 461–484.
